



Community Pharmacy Practice Enactments

In addition to the [Emergency Preparedness Tools](#) that already exist to address any disruptions to patient care, the following enactments by regulatory authorities have been made to help pharmacy professionals address evolving challenges in patient access to health care.

It is important that pharmacy professionals understand these enactments, including what authorized activities are permitted under their scopes of practice, and the terms and conditions that apply.

SCPP works closely with other regulatory partners, the provincial government (Ministry of Health (MoH)) and federal government (Health Canada) to respond to developing events. **Should conflicting messaging arise, contact the SCPP to confirm which direction prevails for pharmacy professionals.**

What enactments are currently in place?

Authority	Enactment	Description
Health Canada (HC) Controlled Drugs and Substances Act (CDSA) (subsection 56(1))	Subsection 56(1) Class Exemption for Patients, Practitioners and Pharmacists Prescribing and Providing Controlled Substances in Canada	<p>Dispensing and Prescribing</p> <p>HC’s exemption for controlled substances (e.g. methadone, morphine, methylphenidate, clonazepam) permits pharmacists to:</p> <ul style="list-style-type: none"> • extend prescriptions (prescribing); or • transfer or accept verbal prescriptions from prescribers (dispensing). <p>Practice Requirements: This HC’s exemption does not authorize:</p> <ul style="list-style-type: none"> • initiation of therapy; or • pharmacy technicians, or pharmacy interns (extended/student) to do any of the above. <p>For further guidance see:</p> <ul style="list-style-type: none"> • SCPP Section 56 Exemption Communication; • “PRP Joint Statement on the s. 56 Exemption for CDSA Drugs” section below; and • Drug Distribution by Prescription. <p>Timeframe:</p> <ul style="list-style-type: none"> • In effect until Sept. 30, 2026, or as otherwise communicated by Health Canada.

	Authority	Enactment	Description
Regulatory Bodies	<p>CDSS Regulatory Bylaws (subsection 13(3))</p> <p>and</p> <p>CPSS Regulatory Bylaws (subsection 18.1(f))</p> <p>and</p> <p>CRNS Regulatory Bylaws (subsection 4(5.1) of Bylaw VI)</p> <p>and</p> <p>SCPP Regulatory Bylaws (s. 4 of Part O)</p>	<p>Prescription Review Program (PRP): Joint Statement on the Section 56 Exemption for CDSA Drugs</p> <p>Verbal Prescriptions Permitted & Prescription Transfers.</p>	<p>Dispensing</p> <p>The PRP partners have agreed to the following provisions to coordinate with HC’s subsection 56(1) exemption:</p> <ul style="list-style-type: none"> • Prescribers may provide verbal orders for drugs listed in the PRP as a last resort if written or electronic options are not available; and • Prescriptions for controlled substances may be transferred one time only. <p>For further guidance see:</p> <ul style="list-style-type: none"> • SCPP’s Section 56 Exemption Communication • Prescription Review Program (PRP). <p>Timeframe:</p> <ul style="list-style-type: none"> • PRP exemption is in effect to correspond with HC’s subsection 56(1) exemption (until Sept. 30, 2026) unless otherwise communicated by the SCPP Registrar.
Provincial	<p>Other Diseases Identified by the Minister of Health or Designate (Part K, s. 19)</p>	<p>Disease: Novel coronavirus disease 2019 (COVID-19)</p> <p>Authorization of pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) under the Paxlovid Distribution, Prescribing and Assessment program.</p>	<p>Prescribing</p> <p>To support this publicly-funded program, pharmacists may only prescribe Paxlovid under the following terms and conditions established by the MoH and the SCPP, including:</p> <ul style="list-style-type: none"> • Eligible patients as per medSask guidelines; • Mandatory training: <ul style="list-style-type: none"> ○ Level 1 Prescriptive Authority – USask CPE ○ Minor Ailment Basics – USask CPE ○ Prescribing Paxlovid (nirmatrelvir and ritonavir) for COVID-19 – USask CPE (if not previously taken) • Practice requirements: <ul style="list-style-type: none"> ○ medSask Guidelines & PAR must be used; ○ MoH program requirements (see DPEBB website & MoH website); ○ Other Diseases – Paxlovid; ○ General Provisions for Prescribing Authority. <p>Monitor SCPP & MoH communications for updates.</p>

Authority	Enactment	Description
		<p>Timeframe:</p> <ul style="list-style-type: none"> In effect until Mar. 31, 2024, or as otherwise communicated by the MoH.
Other Diseases Identified by the Minister of Health or Designate (Part K, s. 19)	<p>Disease: Respiratory syncytial virus (RSV)</p> <p>Authorization of pharmacists to prescribe the RSV vaccine (i.e. Arexvy)</p>	<p>Prescribing</p> <p>Pharmacists must only prescribe Arexvy within the terms and conditions established by the MoH and the SCPP, including:</p> <ul style="list-style-type: none"> Eligible patients as per medSask guidelines; Mandatory training: <ul style="list-style-type: none"> Level 1 Prescriptive Authority – USask CPE Minor Ailment Basics – USask CPE Advanced Method Certification (AMC) – USask CPE (AMC must be current) Practice requirements: <ul style="list-style-type: none"> medSask Guidelines & PAR must be used; General Provisions for Prescribing Authority. <p>Monitor SCPP communications for updates.</p> <p>Timeframe:</p> <ul style="list-style-type: none"> In effect until otherwise communicated by the SCPP.
Other Diseases Identified by the Minister of Health or Designate (Part K, s. 19)	<p>Disease: Seasonal influenza</p> <p>Authorization of pharmacists to prescribe influenza antivirals (i.e. oseltamivir & zanamivir)</p>	<p>Prescribing</p> <p>Pharmacists must only prescribe influenza antivirals within the terms and conditions established by the MoH and the SCPP, including:</p> <p>Timeframe:</p> <ul style="list-style-type: none"> Expired Mar. 31, 2024.
Other Diseases Identified by the Minister of Health or Designate (Part K, s. 19)	<p>Disease: Influenza</p> <p>Authorization of pharmacists to support influenza outbreaks when requested by a Medical Health Officer.</p>	<p>Prescribing</p> <p>To support public health when influenza outbreaks are declared by a Medical Health Officer (e.g. see here), pharmacists may only prescribe influenza antivirals within the terms and conditions established by the Medical Health Officer and the SCPP.</p> <p>Timeframe:</p> <ul style="list-style-type: none"> Expired Mar. 31, 2024.

Authority	Enactment	Description
<p>Ministerial Order under The Public Health Act, 1994 (s. 37.1)</p>	<p>COVID-19 Vaccination Plan & Annual Influenza Immunization Program</p> <p>Additional Vaccine Providers for COVID-19 and Influenza Vaccine.</p>	<p>Administration by Injection</p> <p>Additional Vaccine Providers (pharmacist extended interns, pharmacist students, and pharmacy technicians) are enabled through emergency provisions (see Ministerial Order).</p> <p>Practice Requirements:</p> <ul style="list-style-type: none"> • COVID-19 Immunizers FAQs; • Administration of Drugs by Injection and Other Routes Guidelines and FAQs; • Saskatchewan Drug Plan website for additional terms and conditions. <p>Notes:</p> <ul style="list-style-type: none"> • Pharmacist extended interns, pharmacist students, and pharmacy technicians may only administer the publicly-funded vaccines provided by the COVID-19 or influenza immunization programs, they may not administer other drugs and vaccines. • When hiring a non-pharmacy professional, employers must work with, or have the professional check with their regulatory body to confirm any additional measures required when working in a private practice setting. (See Saskatchewan Immunization Manual, Ch. 2 for additional authorized immunizers (e.g. registered nurses, licensed practical nurses, paramedics)). <p>Timeframe:</p> <ul style="list-style-type: none"> • In effect until March 31, 2025, as authorized in the “Minister’s Order Designating Additional Vaccine Providers for COVID-19 and Influenza Vaccine.”